Previous Article | Next Article 
Antimicrobial Agents and Chemotherapy, January 2000, p. 88-96, Vol. 44, No. 1
0066-4804/0/$04.00+0
Copyright © 2000, American Society for Microbiology. All rights reserved.
In Vitro Activity of Riboflavin against the Human
Malaria Parasite Plasmodium falciparum
Thomas
Akompong,1,*
Nafisa
Ghori,2 and
Kasturi
Haldar1
Departments of Pathology and
Microbiology-Immunology, Northwestern University Medical School,
Chicago, Illinois 60611-3008,1 and
Department of Microbiology and Immunology, Stanford
University School of Medicine, Stanford, California
94305-51242
Received 20 April 1999/Returned for modification 18 June
1999/Accepted 15 October 1999
 |
ABSTRACT |
The human malaria parasite Plasmodium falciparum
digests hemoglobin and polymerizes the released free heme into
hemozoin. This activity occurs in an acidic organelle called the food
vacuole and is essential for survival of the parasite in erythrocytes. Since acidic conditions are known to enhance the auto-oxidation of
hemoglobin, we investigated whether hemoglobin ingested by the parasite
was oxidized and whether the oxidation process could be a target
for chemotherapy against malaria. We released parasites from their host
cells and separately analyzed hemoglobin ingested by the parasites from
that remaining in the erythrocytes. Isolated parasites contained
elevated amounts (38.5% ± 3.5%) of oxidized hemoglobin
(methemoglobin) compared to levels (0.8% ± 0.2%) found in normal, uninfected erythrocytes. Further, treatment of infected cells with the reducing agent riboflavin for 24 h decreased the parasite methemoglobin level by 55%. It also
inhibited hemozoin production by 50% and decreased the
average size of the food vacuole by 47%. Administration of riboflavin
for 48 h resulted in a 65% decrease in food vacuole size and
inhibited asexual parasite growth in cultures. High doses of riboflavin
are used clinically to treat congenital methemoglobinemia
without any adverse side effects. This activity, in conjunction with
its impressive antimalarial activity, makes riboflavin attractive as a
safe and inexpensive drug for treating malaria caused by P. falciparum.
 |
INTRODUCTION |
Malaria infects 300 to 500 million
people and kills about 1 million people, mostly children, each year. In
most areas of endemicity, there are significant levels of resistance to
many antimalarial agents, and in extreme cases, the disease can be
resistant to all known antimalarial agents. Hence, the importance of
discovering new drugs that can be used to combat resistant strains
cannot be overemphasized.
The malaria parasite ingests 25 to 80% of its host erythrocyte
hemoglobin (2, 11, 24, 27) and digests it in an acidic organelle called the food vacuole (fv). Multiple enzymes catalyze this
digestion, and the released heme is detoxified into hemozoin in the fv.
The degradative enzymes, as well as the process of heme detoxification,
have been considered targets of several antimalarial agents. Drugs that
act against these targets include quinoline-based compounds
(28), protease inhibitors (26), and free-radical generators, such as artemisinin and its derivatives (16,
23). However, redox mechanisms and treatments that regulate the
valence state of hemoglobin and their antimalarial potential remain
largely unexplored.
In erythrocytes, hemoglobin is converted from the ferrous to the ferric
or methemoglobin state at a very slow rate under
physiological conditions. This auto-oxidation reaction is accelerated
by chloride and other small anions that may function by displacing the
superoxide anion from oxyhemoglobin. Lower pH and polyanions also
accelerate the process (20, 21). Levels of
methemoglobin in Plasmodium falciparum-infected
erythrocytes have been previously measured. Friedman et al. showed that
cultures with high levels of parasitemia contained 3 to 10 times more
methemoglobin than those with low levels of parasitemia
(10). More recently, Vander Jagt et al. found elevated
methemoglobin levels in isolated fv's but not in crude
lysates of infected or uninfected erythrocytes (32). In contrast, Hempelmann et al. reported no change in the
methemoglobin content of P. falciparum-infected
versus uninfected erythrocytes (14).
Since the end product of hemoglobin digestion in the fv is hemozoin, a
polymer of hematin in the oxidized Fe3+ state, at some step
during ingestion and/or digestion, Fe2+ from hemoglobin has
to be oxidized to Fe3+. If methemoglobin is
formed, since it has a net positive charge and hemoglobin is a neutral
molecule, the charge difference may affect the mechanism of hemoglobin
digestion. We therefore reexamined the possibility that ingested
hemoglobin may be oxidized to methemoglobin. We used two
independent methods to determine the methemoglobin content
of isolated parasites and erythrocytes and report that the malaria
parasite P. falciparum does indeed induce an increase in the
oxidation of hemoglobin to methemoglobin. This activity occurs only in parasites and not in erythrocytes and is thus restricted to ingested hemoglobin. We also show that treatment with riboflavin, which can reduce methemoglobin to hemoglobin in vitro
(15, 18, 22), results in a decrease in the
methemoglobin content of the parasite, inhibits fv
development and function, and inhibits asexual parasite growth in
erythrocytes. A mechanism for the antimalarial action of riboflavin is proposed.
 |
MATERIALS AND METHODS |
Culturing of parasites and drug treatments.
RPMI 1640 medium
and A+ human serum were obtained from GIBCO/BRL and Gemini
Biological Products (Calabasas, Calif.), respectively. Riboflavin was
obtained from Sigma (St. Louis, Mo.). Chloroquine-resistant P. falciparum FCB was cultured in vitro by a modification of the methods of Trager and Jensen (31) and Haldar et al.
(12). The parasites were synchronized by incubation in 5 volumes of 5% sorbitol for 10 min at 37°C. The effect of riboflavin
was determined by incubating cultures of young ring-stage parasites (9 to 15 h) at 5 to 20% parasitemia with 10 to 100 µM riboflavin
for 16 to 48 h. Inhibition of parasite growth was measured by
examining Giemsa-stained blood smears after 48 h of treatment.
Isolation of parasites and separation of associated
proteins.
Cells from infected cultures were washed three times
with phosphate-buffered saline (PBS). The erythrocytes were mixed with 10 volumes of 0.01% saponin in PBS and incubated at 4°C for 10 min.
This procedure selectively lysed erythrocyte but not parasite membranes. The lysate was subjected to centrifugation at
2,200 × g for 10 min, and the supernatant (enriched in
erythrocyte cytosolic content) was removed. The pellet containing
isolated parasites was washed three times with cold PBS, solubilized in
5 volumes of sodium dodecyl sulfate (SDS)-polyacrylamide gel
electrophoresis (PAGE) sample buffer, boiled for 3 to 5 min, and
analyzed by SDS-PAGE (19).
Spectrophotometric assay for determination of
methemoglobin in cell lysates.
The
methemoglobin content of cells was determined by a
modification of the method of Evelyn and Malloy (9).
Briefly, 109 uninfected erythrocytes or 108 to
109 isolated parasites were lysed in 500 µl of distilled
water at room temperature. A total of 400 µl of 0.5 M phosphate
buffer (pH 6.1) was added to 600 µl of the cell lysate, and the
mixture was centrifuged at 16,000 × g for 5 min to
sediment debris. A total of 700 µl of the supernatant fraction was
used to measure the optical density at 630 nm (the absorbance maximum
for methemoglobin), and the reading was recorded as S1. A
total of 50 µl of 10% KCN was added, and after 3 to 5 min at room
temperature, a second reading (S2) was recorded. KCN converts
methemoglobin to cyanomethemoglobin, which does
not absorb at 630 nm; hence, the difference between absorbance readings
S1 and S2 represents the absorbance due to methemoglobin.
To measure total hemoglobin levels, all of the hemoglobin was converted
to methemoglobin, the absorbance of the sample at 630 nm
was recorded, and then KCN was added to form cyanomethemoglobin. Specifically, 70 µl of the
supernatant fraction was diluted 10-fold into 600 µl of 0.1 M
phosphate buffer (pH 6.1). Next, 30 µl of freshly prepared 20%
K3Fe(CN)6 (potassium ferricyanide) was added
and incubated for 3 to 5 min at room temperature, and an initial
reading (T1) was recorded. A total of 50 µl of 10% KCN was
subsequently added, and a second reading (T2) was recorded. The
percent methemoglobin in the sample was
calculated as [100(S1
S2)]/[10(T1
T2)].
Oxidation of hemoglobin in vitro.
Erythrocytes (5 × 107) were lysed in 500 µl of distilled water at room
temperature for 5 min. A total of 5 µl of 20% potassium ferricyanide was added (to convert hemoglobin to
methemoglobin) to the lysate at room temperature for 5 min.
Erythrocyte ghosts were removed by centrifugation at
16,000 × g for 5 min, and the supernatant (containing
1 × 106 to 2 × 106
erythrocyte equivalents) was analyzed by SDS-PAGE and Western blotting.
Peroxidase activity and hemoglobin content after SDS-PAGE.
Proteins from saponin-lysed parasites, supernatants of sorbitol-lysed
infected erythrocytes, or supernatants of saponin-lysed uninfected
erythrocytes were subjected to SDS-PAGE under nonreducing conditions.
The separated proteins were transferred to nitrocellulose membranes at
100 V for 1.5 h at 4°C.
Peroxidase activity was detected by chemiluminescence as described by
Dorward (6). Briefly, the filters were washed with PBS and
incubated for 1 min with enhanced chemiluminescence (ECL) reagent
(Amersham Pharmacia Biotech, Piscataway, N.J.). The filters were then
covered with plastic wrap and exposed to film for 1 to 30 min. For
hemoglobin content determination, the filters were washed with PBS and
incubated with 5% nonfat dry milk for 30 min to quench all endogenous
peroxidase activity. They were subsequently incubated with
antihemoglobin antibody (1:500) for 1 h at room temperature,
washed with Tris-buffered saline containing 0.05% Tween 20, and
incubated with peroxidase-conjugated secondary antibody (1:1,500) for
1 h at room temperature. The bands were developed with ECL
solutions in accordance with the manufacturer's protocol. Polyclonal
rabbit anti-human hemoglobin antibody was from Dako (Carpinteria,
Calif.).
Quantitative measurement of hemoglobin ingested and hemozoin
produced in the presence or absence of riboflavin.
Cells were
collected by centrifugation, washed three times with PBS, and
resuspended in 5 volumes of 5% sorbitol for 20 min at room
temperature. This procedure released hemoglobin from infected cells.
The cell lysate was subjected to stepwise centrifugation at
600 × g for 7 min and 2,200 × g for
10 min to separately sediment uninfected erythrocytes and parasites
contained within erythrocyte ghosts. The hemoglobin content of the
supernatant fraction was determined by measuring the optical density at
540 nm.
Uninfected cells obtained after the first centrifugation step at
600 × g were treated with 0.01% saponin in RPMI 1640 medium at room temperature for 10 min. This procedure released
intracellular hemoglobin, which was quantitated by measuring the
absorbance of the cleared supernatant at 540 nm. The number of moles of
hemoglobin in infected and uninfected erythrocytes was calculated based
on the number of erythrocytes in the culture, the percent parasitemia, and the millimolar extinction coefficient of 14.61 for hemoglobin (7). The amount of hemoglobin ingested by parasites was
obtained by subtracting the amount of hemoglobin released from the
erythrocyte cytosol of infected cells by sorbitol treatment from the
total amount released from uninfected cells by saponin.
To release hemozoin from parasites, infected cells were first lysed
with 0.01% saponin for 10 min at room temperature to release parasites
from erythrocyte ghosts. The parasites were washed three times with
PBS, resuspended in 2.5% SDS in PBS, and subjected to centrifugation
at 20,000 × g for 1 h. The supernatant was
discarded, and the insoluble pellet was washed in 2.5% SDS in PBS and
then dissolved in 20 mM NaOH. The hemozoin content was measured by determining the absorbance at 400 nm and using a standard curve generated with hematin.
Electron microscopy.
Cultures of ring-infected erythrocytes
were incubated with riboflavin (15 to 100 µM) for 16 to 48 h.
Mock- and riboflavin-treated infected erythrocytes were fixed in PBS
containing 2% glutaraldehyde at 4°C for 30 min and processed to be
embedded in Spurr's resin, and thin sections were examined in a
Philips CM-12 microscope. fv diameters were measured, and their
statistical variation was assessed by a one-way analysis of variance
with the Tukey test for multiple comparisons between means.
 |
RESULTS |
Methemoglobin content of isolated parasites and P. falciparum-infected and uninfected erythrocytes.
Oxidation
of hemoglobin to methemoglobin results in marked changes in
the chemical and spectral properties of the molecule. For instance,
methemoglobin does not bind oxygen, a major physiological function of hemoglobin. The absorbance maximum of
methemoglobin is 630 nm, which is red shifted about 100 nm
relative to that of hemoglobin. Thus, measurement of the absorbance at
630 nm affords a simple spectrophotometric method of
distinguishing between the two species. We therefore exploited
this difference to determine the fraction of methemoglobin
present in isolated parasites and uninfected erythrocytes. We found
that in isolated parasites, the methemoglobin content was
20 to 42% the total hemoglobin content. In contrast, in erythrocytes,
this fraction was 0.5 to 1%. These results suggested that the parasite
induced an increase in methemoglobin. The fact that
increased methemoglobin was detected in isolated parasites
reflects oxidation of ingested hemoglobin.
Although the spectrophotometric assay is a standard method for
determining the methemoglobin content of blood samples, it is possible that some parasite proteins and products, such as hemozoin,
could interfere with the determinations. Thus, we developed a second
method in which we exploited the intrinsic peroxidase activity of
heme-containing compounds, which is dependent on the oxidation state of
heme iron and can be measured by chemiluminescence (6).
We first established the elevated peroxidase activity of
methemoglobin produced in vitro. This was done by treating
hemoglobin obtained from erythrocyte cytosol with potassium
ferricyanide [K3Fe(CN)6] at room temperature
for 5 min. As shown in Fig. 1A, panel I,
the peroxidase activity was higher in ferricyanide-treated hemoglobin
than in untreated hemoglobin, even though there were comparable amounts
of protein (as measured by immunoblotting with antibodies; Fig.
1A, panel II) in the two samples. (The intrinsic peroxidase activity of hemoglobin did not interfere with the immunoblot determination because the endogenous activity is completely quenched after blocking with nonfat dry milk, a standard precaution of the ECL
method). This result indicated that chemiluminescence associated
with the 14-kDa gel-purified hemoglobin band may be used to
determine the relative methemoglobin content of a sample.

View larger version (43K):
[in this window]
[in a new window]
|
FIG. 1.
Peroxidase activity associated with
methemoglobin formed in vitro and in vivo. (A) Uninfected
erythrocytes (RBC) were lysed hypotonically, the cytosolic fraction was
incubated in the absence or presence of potassium ferricyanide (to form
methemoglobin), and the proteins were separated by
SDS-PAGE, transferred to nitrocellulose, and assayed for peroxidase
activity or immunoblotted for hemoglobin content. Molecular masses are
indicated in kilodaltons. (B) Trophozoite-infected erythrocytes
were lysed with sorbitol, and the supernatant fraction (sup.) was
separated from isolated parasites in the pellet fraction. Both
fractions were assayed for peroxidase activity and
hemoglobin content as described for panel A. (C) Uninfected
erythrocytes (U) and parasites at the indicated times of growth were
isolated by lysing infected erythrocytes with saponin and analyzed
for peroxidase activity and hemoglobin content as described for panel
A. Hemozoin was also determined, as indicated at the bottom of panel
II.
|
|
In this assay, parasites released from erythrocytes by sorbitol
treatment had higher levels of peroxidase activity than the sorbitol
supernatant, containing hemoglobin from the host cytoplasm (Fig. 1B,
panel I). However, the total amount of hemoglobin in the sorbitol
supernatant was much higher than that in isolated parasites (Fig. 1B,
panel II). These data suggest that isolated parasites contain a larger
fraction of methemoglobin than erythrocyte cytosol, are
consistent with those obtained by the standard spectrophotometric assay
(see above), and support the hypothesis that P. falciparum oxidizes ingested hemoglobin.
As a consequence of hemoglobin degradation, free heme
is released and polymerized into hemozoin. To correlate the
increase in hemoglobin oxidation to hemozoin formation during the
asexual life cycle, peroxidase activities and levels of hemoglobin and hemozoin were measured at the different intracellular stages of the
parasite. To do this, cells were collected from synchronized cultures
every 6 h, parasites were separated from erythrocyte membranes by treatment with 0.01% saponin, and proteins
were separated by SDS-PAGE. As shown in Fig. 1C, hemoglobin was
detected in association with parasites as early as 9 h after
invasion. This result suggests that even early ring-stage parasites may
ingest low levels of hemoglobin. However, there was no increased
peroxidase activity symptomatic of induced hemoglobin oxidation in
ring-stage parasites relative to uninfected cells. In contrast,
parasite-associated peroxidase activity increased during the
trophozoite and schizont stages (>27 h) of development. This result
indicated that a higher level of hemoglobin oxidation occurred at these
later stages. This increase in peroxidase activity paralleled the
increase in hemozoin production (see lower half of Fig. 1C, panel II),
suggesting that the two may be linked.
The levels of hemoglobin detected in the saponin-isolated
parasites in our study are much higher than those previously
reported by Rosenthal (25). However, the
conditions of parasite isolation in that study differ from those in our
study. Whereas Rosenthal isolated parasites with 0.1% saponin at
37°C for 15 min, we used a milder isolation procedure of 0.01%
saponin at 4°C for 10 min. This mild isolation protocol minimized
protein degradation during isolation, possibly explaining why larger
amounts of hemoglobin were detected by our method.
Treatment with riboflavin inhibits the formation of
methemoglobin and hemozoin, reduces the size of the fv,
and blocks parasite proliferation in cultures.
Since riboflavin
can reduce methemoglobin to hemoglobin in vitro, we
investigated its effects on methemoglobin in infected erythrocytes. In these assays, ring-stage parasite (9 to 15 h)-infected cells were cultured with or without riboflavin for 16 to
24 h. Parasites were isolated from erythrocytes by treatment with
0.01% saponin, and the methemoglobin content was measured
by both the spectrophotometric and the peroxidase assays. The former
indicated that the methemoglobin level in treated
cells was 17.5% ± 2.5%, considerably lower than that found in
control incubations (38.5% ± 3.5%. The peroxidase activity in
treated parasites was also significantly reduced (Fig.
2A, panel I), although the total
amounts of hemoglobin were comparable in both samples (Fig. 2A,
panel II). These results indicate that riboflavin-treated
parasites contain less methemoglobin than untreated
parasites. The chemiluminescence and spectrophotometric assays both
indicated a 50% reduction in methemoglobin
formation. This result further supports the notion that
chemiluminescence associated with the 14-kDa band from isolated parasites is due to methemoglobin. There was a
concomitant 50% reduction in hemozoin levels, although no significant
change was detected in amounts of hemoglobin ingested by
parasites (Fig. 2B). These results suggest that riboflavin treatment
reduces hemozoin formation and are consistent with the hypothesis that
hemoglobin oxidation is important for hemozoin formation in P. falciparum.

View larger version (26K):
[in this window]
[in a new window]
|
FIG. 2.
Effects of riboflavin on the peroxidase activity of
methemoglobin, hemozoin formation, and hemoglobin uptake.
Cultures of ring-stage parasite-infected erythrocytes were incubated in
the absence or presence of 100 µM riboflavin for 24 h, and
parasites were isolated by saponin lysis. (A) Peroxidase activity and
hemoglobin content were determined as described in the legend to Fig.
1A. (B) Levels of hemozoin produced (open bars) were determined by
conversion to hematin. The amount of hemoglobin ingested (by the
parasite) (solid bars) was derived by subtracting the amount of
hemoglobin released (by sorbitol lysis) from the cytosol of infected
erythrocytes from the total hemoglobin content found in uninfected
erythrocytes. The bars represent the mean of three independent
determinations ± the standard error of the mean.
|
|
Hemozoin production is restricted to the fv. To examine whether
riboflavin treatment affects the ultrastructure or size of the fv,
ring-stage parasite-infected cells were incubated in the absence or
presence of riboflavin. The cells were processed for transmission
electron microscopy after 24 or 48 h of incubation. Examination of
thin sections showed that the average diameter of the fv was
significantly reduced in treated cells. The average fv diameter
after 24 h of treatment was 1.0 ± 0.08 µm, compared to
1.86 ± 0.1 µm in mock-treated cells (P,
<0.001) (Fig. 3A, B, and
D). Treatment for 48 h caused a further reduction in the diameter of the fv (0.66 ± 0.06 µm) (Fig. 3C and D), which was statistically significant
(P, <0.009) compared to the effect seen after 24 h.




View larger version (12513412434K):
[in this window]
[in a new window]
|
FIG. 3.
Effects of riboflavin on the morphology of the fv.
Infected erythrocytes were treated with or without riboflavin (100 µM) for the indicated times and prepared for electron microscopy by
embedding in Spurr's resin, and thin sections were obtained. (A)
Mock-treated infected erythrocyte. (B and C) Infected erythrocytes
treated with riboflavin for 24 and 48 h, respectively. hz,
hemozoin; p, parasite; e, erythrocyte. Scale bars, 5 µm. (D) fv
diameters measured in ultrathin sections from cells that were mock
treated or treated with riboflavin for 24 or 48 h. The bars
represent the mean ± standard error of the mean. A total of 48 sections were measured.
|
|
The digestion of hemoglobin and hemozoin production are thought to be
essential for parasite growth. Since exposure to riboflavin is
inhibitory to both, we examined its effects on parasite maturation in
the asexual life cycle. In a dose-response study, erythrocytes infected
with ring-stage parasites were incubated with 10 to 100 µM riboflavin
for 48 h. As shown in Table 1, 15 to
100 µM riboflavin inhibited parasite growth, but parasites in the
different treatment groups were not at the same stages of development.
At 10 to 15 µM riboflavin, the parasites had largely progressed to
form new ring-stage parasites, like untreated parasites. However, at 20 to 25 µM riboflavin, trophozoites from the first cycle that
failed to mature were also detected in the culture. Incubation with 50 to 100 µM riboflavin completely inhibited asexual parasite
maturation, such that no multinucleated trophozoites or schizonts or
new ring-stage parasites were seen in the culture. A significant
proportion of parasites in this group was surrounded by ghost
erythrocyte membranes, and the cytosol showed an abnormal pink stain in
Giemsa-stained smears, consistent with the accumulation of undigested
hemoglobin.
To examine whether riboflavin affects another target(s) in addition to
fv, trophozoite-stage parasites that contained a fully developed fv
were cultured for 24 h with different concentrations of
riboflavin. As shown in Table 2, at all
concentrations of riboflavin tested, parasitemia was significantly
reduced (85 to 93%). This result suggests that there may be another
riboflavin-sensitive target(s) besides the fv.
In summary, there may be at least two riboflavin-sensitive sites in the
parasite. One is the fv, where the inhibition of
methemoglobin and hemozoin formation and a reduction in fv
size correlate with a block in asexual parasite maturation to
schizogony. Additional targets presently unknown remain sensitive to
riboflavin after the fv is formed.
 |
DISCUSSION |
We provide strong evidence that the malaria parasite converts
hemoglobin to methemoglobin and that this process can be
inhibited by riboflavin. Although the heme pocket, with its
hydrophobic structure, shields the ferrous iron against
oxidation, low levels of hemoglobin are continuously oxidized in
erythrocytes. Under normal conditions, methemoglobin in
erythrocytes is reduced by NADH-cytochrome
b5/cytochrome
b5 reductase and maintained at levels below 1%.
However, when methemoglobin content increases due to the
presence of oxidant drugs, increased pH, or other exogenous factors, the reducing capacity of the enzyme may be exceeded. Methylene
blue or riboflavin is used to treat patients with high levels of
methemoglobin. The proposed mechanism of action of these compounds involves their reduction by NADPH-methemoglobin
reductase and the subsequent reduction of methemoglobin by
reduced methylene blue or riboflavin. The Km of
human NADPH-methemoglobin reductase for riboflavin is 50 µM (33); therefore, 10 to 100 µM riboflavin was used in
our experiments.
The malaria parasite ingests a significant proportion of host cell
hemoglobin in the fv, whose acidic pH is favorable to the oxidation of
hemoglobin to methemoglobin (20). Friedman et
al. used spectrophotometric methods to show that a higher
level of infection results in a higher methemoglobin
content (10). However, Hempelmann et al. compared the
methemoglobin levels of uninfected and P. falciparum-infected erythrocytes by isoelectric gel
electrophoresis (14) and found no difference. Thus, the
oxidation state of hemoglobin in P. falciparum remains
unresolved. Specifically, Hempelmann et al. did not account for
monomers and dimers of methemoglobin formed as a result of
partial digestion of hemoglobin in the fv, and Friedman et al. did not
resolve whether the increase in hemoglobin oxidation occurred in the
erythrocyte or in the parasite.
We used two different methods to show that the
methemoglobin content in the malaria parasite was indeed
elevated and that ingested hemoglobin was oxidized during processing.
In the spectrophotometric method, the difference in absorbance at 630 nm with or without KCN was used to establish that the
methemoglobin content of isolated P. falciparum
was higher than that of infected or uninfected erythrocyte cytosol.
Hemozoin interferes with hemoglobin measurement at 540 nm
(27), raising the issue of whether it affects the
spectrophotometric measurement of methemoglobin. However,
this is unlikely for two reasons. First, methemoglobin is
measured as a net difference in absorbance. Second, the measurement is
done at an acidic pH, at which hemozoin is insoluble and thus is
not present in the high-speed supernatant that contains hemoglobin.
We have developed a new method of estimating the relative
methemoglobin content of unknown samples based on the
observation that methemoglobin has higher peroxidase
activity than hemoglobin. The major advantages of this method over the
spectrophotometric determination are that it uses 10- to 100-fold less
material and measures the activity of proteins that are purified by
SDS-PAGE, thus minimizing contamination from other proteins and
hemozoin. Using the peroxidase assay, we confirmed that the parasite
induces an increase in hemoglobin oxidation inside the parasite and not in the infected erythrocyte cytosol. The induction of oxidation is
higher in trophozoites and schizonts than in ring-stage parasites. Since hemozoin formation occurs in trophozoites and schizonts, it is
possible that the oxidation process is necessary for hemozoin formation. Our results are consistent with those of Vander Jagt et al.,
who showed by visible-absorption-spectrum measurements that isolated
fv's contained a mixture of hemoglobin and methemoglobin, whereas infected or uninfected erythrocyte lysates contained only native hemoglobin (32).
In preliminary studies, we found that 1 nM methylene blue killed
ring-stage parasites (data not shown), as previously reported in the
literature (1). However, since we detected no appreciable methemoglobin formation during the ring stage, the
mechanism of action of methylene blue may not involve the reduction of
methemoglobin in the parasite. It is possible that
methylene blue and riboflavin have distinct targets in the parasite.
Unlike treatment with methylene blue, treatment with riboflavin (up to
500 µM) had no effect on ring-stage parasites. In contrast, treatment
of ring-stage parasites with 50 to 100 µM riboflavin for 24 h
reduced methemoglobin content and hemozoin formation by
more than 50%. Thus, methemoglobin reduction, inhibition
of hemozoin formation, fv development, and arrest of asexual parasite
development to schizogony are correlated, suggesting that these events
may be linked.
The effects of riboflavin reported here apparently differ from those
reported in previous studies showing that the ability of infants from
Papua New Guinea to suppress P. falciparum infections is correlated with riboflavin deficiency (30). P. berghei-infected rats fed a riboflavin-deficient diet
were also able to suppress the initial infection better than control
rats (17). These results led Dutta et al. (8) to
suggest that riboflavin deficiency could be used to treat human
malaria. However, as pointed out by Thurnham (29), the
effect of nutrient deficiency on parasite growth is not limited to
riboflavin but, in general, nutrient deprivation is detrimental to both
parasite and host. The reason for the antimalarial activity of
riboflavin deficiency may be due to a decrease in the activity of
reductive enzymes such as glutathione reductase, which require
riboflavin as a cofactor. This decreased activity lowers
glutathione levels, resulting in increased lipid peroxidation
(5), which is detrimental to the parasite (oxidative
stress hypothesis). Consistent with the oxidative stress hypothesis,
several riboflavin and flavin analogues have been shown to have
antimalarial activity (3, 4, 13), but their mode of action
may not be through the inhibition of the glutathione reducing system
(13).
We propose that the continued reduction of methemoglobin by
riboflavin creates a futile cycle (Fig.
4) in which hemoglobin is continually
oxidized (since the conditions in the fv favor oxidation) and reduced.
The model predicts that hemozoin formation will be inhibited, since the
cycle reduces the amount of methemoglobin and/or hemoglobin
available for further processing. The continued utilization of NADPH
means that its availability to enzymes, such as glutathione reductase,
that require this cofactor for activity will be severely limited.
The sum total of these effects would culminate in the arrest of
parasite maturation and differentiation.

View larger version (16K):
[in this window]
[in a new window]
|
FIG. 4.
Proposed model for hemoglobin oxidation and riboflavin
action in P. falciparum-infected erythrocytes.
|
|
In conclusion, riboflavin severely affects the development and function
of the fv of P. falciparum. The concentrations required for
its antimalarial activity are similar to those used to treat human
patients with congenital methemoglobinemia over several years with no adverse effects. The presence of two or more targets for
riboflavin in P. falciparum favors its use as an
antimalarial agent because this characteristic decreases the
probability of the emergence of resistant strains.
 |
ACKNOWLEDGMENTS |
This work was supported by NIH grant AI39071 and a Burroughs
Wellcome New Initiatives in Malaria award (to K.H.).
We thank Daniel Goldberg for comments on the manuscript and N. Luisa
Hiller and Paul Cheresh for reading and editing the manuscript.
 |
FOOTNOTES |
*
Corresponding author. Mailing address: Departments of
Pathology and Microbiology-Immunology, Northwestern University Medical School, 303 E. Chicago Ave., Chicago, IL 60611-3008. Phone: (312) 503-1443. Fax: (312) 503-0281. E-mail: t-akompong{at}nwu.edu.
 |
REFERENCES |
| 1.
|
Atamna, H.,
M. Krugliak,
G. Shalmiev,
E. Deharo,
G. Pescarmona, and H. Ginsburg.
1996.
Mode of antimalarial effect of methylene blue and some of its analogues on Plasmodium falciparum in culture and their inhibition of P. vinckei petteri and P. yoeli nigeriensis in vivo.
Biochem. Pharmacol.
51:693-700[CrossRef][Medline].
|
| 2.
|
Ball, E. G.,
R. W. McKee,
C. B. Anfinsen,
W. O. Cruz, and Q. M. Giman.
1948.
Studies on malarial parasites. IX. Chemical and metabolic changes during growth and multiplication in vivo and in vitro.
J. Biol. Chem.
175:547-571[Free Full Text].
|
| 3.
|
Becker, K.,
R. Christopherson,
W. Cowden,
N. Hunt, and R. Schirmer.
1990.
Flavin analogs with antimalarial activity as glutathione reductase inhibitors.
Biochem. Pharmacol.
39:59-65[CrossRef][Medline].
|
| 4.
|
Cowden, W.,
B. Geofrey,
N. Hunt,
I. Clark, and F. Yoneda.
1987.
Antimalarial activity of a riboflavin analog against Plasmodium vinckei in vivo and Plasmodium falciparum in vitro.
Am. J. Trop. Med. Hyg.
37:495-500.
|
| 5.
|
Das, B.,
D. Thurnham,
J. Patnaik,
D. Das,
R. Satpathy, and T. Bose.
1990.
Increased plasma lipid peroxidation in riboflavin-deficient, malaria-infected children.
Am. J. Clin. Nutr.
51:859-863[Abstract/Free Full Text].
|
| 6.
|
Dorward, D. W.
1993.
Detection and quantitation of heme-containing proteins by chemiluminescence.
Anal. Biochem.
209:219-223[CrossRef][Medline].
|
| 7.
|
Drabkin, D. L.
1946.
Spectrophotometric studies. XIV. The crystallographic and optical properties of hemoglobin of man in comparison with those of other species.
J. Biol. Chem.
164:703-723[Free Full Text].
|
| 8.
|
Dutta, P.,
J. Pinto, and R. Rivlin.
1985.
Antimalarial effects of riboflavin deficiency.
Lancet
ii:1040-1043[CrossRef].
|
| 9.
|
Evelyn, K., and H. Malloy.
1938.
Micro determination of oxyhemoglobin, methemoglobin, and sulfhemoglobin in a single sample of blood.
J. Biol. Chem.
126:655-662[Free Full Text].
|
| 10.
|
Friedman, M. J.,
E. F. Roth,
R. L. Nagel, and W. Trager.
1979.
Plasmodium falciparum: physiological interactions with the human sickle cell.
Exp. Parasitol.
47:73-80[CrossRef][Medline].
|
| 11.
|
Goldberg, D. E.
1993.
Hemoglobin degradation in Plasmodium-infected red blood cells.
Semin. Cell Biol.
4:355-361[CrossRef][Medline].
|
| 12.
|
Haldar, K.,
M. A. Ferguson, and G. A. Cross.
1985.
Acylation of a Plasmodium falciparum merozoite surface antigen via sn-1,2-diacyl glycerol.
J. Biol. Chem.
260:4969-4974[Abstract/Free Full Text].
|
| 13.
|
Halladay, P. K.,
N. H. Hunt,
G. A. Butcher, and W. B. Cowden.
1990.
Antimalarial action of flavin analogues seems not to be due to inhibition of glutathione reductase of host erythrocytes.
Biochem. Pharmacol.
39:1063-1065[CrossRef][Medline].
|
| 14.
|
Hempelmann, E.,
R. H. Schirmer,
G. Fritsch,
E. Hundt, and U. Groschel-Stewart.
1987.
Studies on glutathione reductase and methemoglobin from human erythrocytes parasitized with Plasmodium falciparum.
Mol. Biochem. Parasitol.
23:19-24[CrossRef][Medline].
|
| 15.
|
Hirano, M.,
T. Matsuki,
K. Tanishima,
M. Takeshita,
S. Shimizu,
Y. Nagamura, and Y. Yoneyama.
1981.
Congenital methaemoglobinaemia due to NADH methemoglobin reductase deficiency: successful treatment with oral riboflavin.
Br. J. Haematol.
47:353-359[Medline].
|
| 16.
|
Hong, Y. L.,
Y. Z. Yang, and S. R. Meshnick.
1994.
The interaction of artemisinin with malarial hemozoin.
Mol. Biochem. Parasitol.
63:121-128[CrossRef][Medline].
|
| 17.
|
Kaikai, P., and D. Thurnham.
1983.
The influence of riboflavin deficiency on Plasmodium berghei infections in rats.
Trans. R. Soc. Trop. Med. Hyg.
77:680-686[CrossRef][Medline].
|
| 18.
|
Kaplan, J., and M. Chirouze.
1978.
Therapy of recessive congenital methaemoglobinaemia by oral riboflavin.
Lancet
ii:1043-1044.
|
| 19.
|
Laemmli, U. K.
1970.
Cleavage of structural proteins during the assembly of the head of bacteriophage T4.
Nature
224:680-685[CrossRef].
|
| 20.
|
Mansouri, A., and K. Winterhalter.
1973.
Nonequivalence of chains in hemoglobin oxidation.
Biochemistry
12:4946-4949[CrossRef][Medline].
|
| 21.
|
Mansouri, A., and K. Winterhalter.
1974.
Nonequivalence of chains in hemoglobin oxidation and oxygen binding. Effect of organic phosphates.
Biochemistry
13:3311-3314[CrossRef][Medline].
|
| 22.
|
Masuki, T.,
T. Yubisui,
A. Tomada,
Y. Yoneyama,
M. Takeshita,
M. Hirano,
K. Kobayashi, and Y. Tani.
1978.
Acceleration of methaemoglobin reduction by riboflavin in human erythrocytes.
Br. J. Haematol.
39:523-528[Medline].
|
| 23.
|
Meshnick, S. R.,
A. Thomas,
A. Ranz,
C. M. Xu, and H. Z. Pan.
1991.
Artemisinin (qinghaosu): the role of intracellular hemin in its mechanism of antimalarial action.
Mol. Biochem. Parasitol.
49:181-189[CrossRef][Medline].
|
| 24.
|
Morrison, D. B., and H. A. Jeskey.
1948.
Alterations in some constituents of the monkey erythrocyte infected with Plasmodium knowlesi as related to pigment formation.
J. Natl. Malar. Soc.
7:259-264.
|
| 25.
|
Rosenthal, P.
1995.
Plasmodium falciparum: effects of proteinase inhibitors on globin hydrolysis by cultured malaria parasites.
Exp. Parasitol.
80:272-281[CrossRef][Medline].
|
| 26.
|
Rosenthal, P.,
W. Wollish,
J. Palmer, and D. Rasnick.
1991.
Antimalarial effects of peptide inhibitors of a Plasmodium falciparum cysteine proteinase.
J. Clin. Investig.
88:1467-1472.
|
| 27.
|
Roth, E. F., Jr.,
D. S. Brotman,
J. P. Vanderberg, and S. Schulman.
1986.
Malarial pigment-dependent error in the estimation of hemoglobin content in Plasmodium falciparum-infected red cells: implications for metabolic and biochemical studies of the erythrocytic phases of malaria.
Am. J. Trop. Med. Hyg.
35:906-911.
|
| 28.
|
Sullivan, D., Jr.,
H. Matile,
R. Ridley, and D. Goldberg.
1998.
A common mechanism for blockade of heme polymerization by antimalarial quinolines.
J. Biol. Chem.
273:31103-31107[Abstract/Free Full Text].
|
| 29.
|
Thurnham, D.
1985.
Antimalarial effects of riboflavin deficiency.
Lancet
ii:1310-1311.
|
| 30.
|
Thurnham, D.,
S. Oppenheimer, and R. Bull.
1983.
Riboflavin status and malaria in infants in Papua New Guinea.
Trans. R. Soc. Trop. Med. Hyg.
77:423-424[CrossRef][Medline].
|
| 31.
|
Trager, W., and J. B. Jensen.
1976.
Human malaria parasites in continuous culture.
Science
193:673-675[Abstract/Free Full Text].
|
| 32.
|
Vander Jagt, D.,
L. Hunsaker,
N. Campos, and J. Scaletti.
1992.
Localization and characterization of hemoglobin-degrading aspartic proteinases from malarial parasite Plasmodium falciparum.
Biochim. Biophys. Acta
1122:256-264[CrossRef][Medline].
|
| 33.
|
Yubisui, T.,
T. Matsuki,
K. Tanishima,
M. Takeshita, and Y. Yoneyama.
1977.
NADPH-flavin reductase in human erythrocytes and the reduction of methemoglobin through flavin by the enzyme.
Biochem. Biophys. Res. Commun.
76:174-182[CrossRef][Medline].
|
Antimicrobial Agents and Chemotherapy, January 2000, p. 88-96, Vol. 44, No. 1
0066-4804/0/$04.00+0
Copyright © 2000, American Society for Microbiology. All rights reserved.
This article has been cited by other articles:
-
Bhattacharya, A., Mishra, L. C., Bhasin, V. K.
(2008). In Vitro Activity of Artemisinin in Combination with Clotrimazole or Heat-treated Amphotericin B against Plasmodium falciparum. Am J Trop Med Hyg
78: 721-728
[Abstract]
[Full Text]
-
VILLAMOR, E., MSAMANGA, G., SAATHOFF, E., FATAKI, M., MANJI, K., FAWZI, W. W.
(2007). EFFECTS OF MATERNAL VITAMIN SUPPLEMENTS ON MALARIA IN CHILDREN BORN TO HIV-INFECTED WOMEN. Am J Trop Med Hyg
76: 1066-1071
[Abstract]
[Full Text]
-
Hogg, T., Nagarajan, K., Herzberg, S., Chen, L., Shen, X., Jiang, H., Wecke, M., Blohmke, C., Hilgenfeld, R., Schmidt, C. L.
(2006). Structural and Functional Characterization of Falcipain-2, a Hemoglobinase from the Malarial Parasite Plasmodium falciparum. J. Biol. Chem.
281: 25425-25437
[Abstract]
[Full Text]
-
Burgess, C., O'Connell-Motherway, M., Sybesma, W., Hugenholtz, J., van Sinderen, D.
(2004). Riboflavin Production in Lactococcus lactis: Potential for In Situ Production of Vitamin-Enriched Foods. Appl. Environ. Microbiol.
70: 5769-5777
[Abstract]
[Full Text]
-
TRAUNMULLER, F., RAMHARTER, M., LAGLER, H., THALHAMMER, F., KREMSNER, P. G., GRANINGER, W., WINKLER, S.
(2003). NORMAL RIBOFLAVIN STATUS IN MALARIA PATIENTS IN GABON. Am J Trop Med Hyg
68: 182-185
[Abstract]
[Full Text]
-
Akompong, T., Kadekoppala, M., Harrison, T., Oksman, A., Goldberg, D. E., Fujioka, H., Samuel, B. U., Sullivan, D., Haldar, K.
(2002). trans Expression of a Plasmodium falciparum Histidine-rich Protein II (HRPII) Reveals Sorting of Soluble Proteins in the Periphery of the Host Erythrocyte and Disrupts Transport to the Malarial Food Vacuole. J. Biol. Chem.
277: 28923-28933
[Abstract]
[Full Text]
-
Akompong, T., Eksi, S., Williamson, K., Haldar, K.
(2000). Gametocytocidal Activity and Synergistic Interactions of Riboflavin with Standard Antimalarial Drugs against Growth of Plasmodium falciparum In Vitro. Antimicrob. Agents Chemother.
44: 3107-3111
[Abstract]
[Full Text]